• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Semler Scientific® Reports Fourth Quarter and Full Year 2024 Financial Results with a BTC Yield of 107% since July 1, 2024; Now holds 3,192 BTC

    2/18/25 4:01:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $SMLR alert in real time by email

    SANTA CLARA, Calif., Feb. 18, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today reported financial results for the fourth quarter and year ended December 31, 2024.

    (PRNewsfoto/Semler Scientific, Inc.)

    "We are again pleased to report strong performance from our healthcare business with income from operations of $20.9 million for the full year 2024," said Doug Murphy-Chutorian, MD, chief executive officer of Semler Scientific. "While we continue to support innovation and growth in our healthcare business, our main use of cash is to acquire and hold bitcoin."

    "2024 was a transformative year for Semler Scientific as we embraced a bitcoin treasury strategy to maximize stockholder value," said Eric Semler, chairman of Semler Scientific. "Through a disciplined and accretive approach, we have acquired 3,192 bitcoins, which are now valued at approximately $300 million. Since launching this strategy in May 2024, our market capitalization has increased more than 200%. We have unwavering confidence in bitcoin's long-term potential and view it as digital gold. With this conviction, we remain committed to significantly expanding our bitcoin holdings."

    BITCOIN TREASURY HIGHLIGHTS AND OTHER RECENT DEVELOPMENTS

    • "BTC Yield" KPI: For the year ended December 31, 2024, Semler Scientific's BTC Yield was 107%. BTC Yield is a key performance indicator (KPI) that Semler Scientific uses to help assess the performance of its strategy of acquiring bitcoin in a manner it believes is accretive to stockholders. See "Important Information about BTC Yield KPI" in this press release for the definition of BTC Yield and how it is calculated.
    • Digital Assets: As of December 31, 2024, Semler Scientific held 2,298 bitcoins with a fair value of $214.6 million, which reflects a cumulative increase in fair value of $24.9 million. During the year ended December 31, 2024, Semler Scientific purchased 2,298 bitcoins for an aggregate cost of $189.7 million. Subsequently through February 14, 2025, Semler Scientific purchased an additional 894 bitcoins for an aggregate cost of $90.7 million. Semler Scientific's total holdings as of February 14, 2025 are 3,192 bitcoins for an aggregate purchase amount of $280.4 million from operating cashflow, monetization of a portion of its minority interest in Monarch Medical Technologies, LLC, as well as proceeds from its ATM and senior convertible notes offerings. All purchase amounts include fees and expenses.
    • At-the-Market Equity Offering Program: Semler Scientific entered into a Controlled Equity Offeringsm Sales Agreement (the Sales Agreement) with Cantor Fitzgerald & Co., pursuant to which it may issue and sell from time to time up to $150.0 million of its common stock in an at-the-market (ATM) offering. As of December 31, 2024, Semler Scientific had sold an aggregate of 2,197,988 shares under the Sales Agreement for aggregate net proceeds (less sales commissions) of approximately $119.6 million.
    • Issuance of 4.25% Convertible Notes due 2030: In January 2025, Semler Scientific issued $100.0 million aggregate principal amount of 4.25% Convertible Senior Notes due 2030 (the Notes), including the exercise in full of the initial purchasers' option to purchase up to an additional $15.0 million principal amount of the Notes. The Notes have an initial conversion price of approximately $76.44 per share of common stock. At the same time, Semler Scientific entered into capped call transactions in connection with the notes with an initial cap price of approximately $107.01 per share of common stock.

    FINANCIAL RESULTS

    For the year ended December 31, 2024, compared to the corresponding period of 2023, Semler Scientific reported:

    • Revenues of $56.3 million, a decrease of $11.9 million, or 17%, compared to $68.2 million.
    • Cost of revenues of $4.8 million, a decrease of $2.2 million or 32% compared to $7.0 million. Cost of revenues for the full year ended December 31, 2023 includes a $2.5 million write-off of prepaid software licenses for Insulin Insights.
    • Total operating expenses, which includes cost of revenues, of $35.4 million, a decrease of $10.5 million, or 23%, compared to $45.9 million.
    • Income from operations of $20.9 million, a decrease of $1.4 million, or 6%, compared to $22.3 million.
    • Pre-tax income of $47.9 million (which includes an unrealized gain from the change in fair value of Semler Scientific's bitcoin holdings of $24.9 million), an increase of $23.8 million, or 99%, compared to $24.1 million.
    • Income tax expense of $7.0 million, or an effective tax rate of 15%, compared to $3.5 million, or an effective tax rate of 15%.
    • Net income of $40.9 million, or $5.66 per basic share and $5.13 per diluted share, an increase of $20.3 million, or 99%, compared to $20.6 million, or $3.06 per basic share and $2.63 per diluted share.

    Semler Scientific's two largest customers (including their affiliates) comprised 43% and 28% of full year revenues in 2024, respectively, and 36% and 35% of full year revenues in 2023, respectively.

    For the fourth quarter ended December 31, 2024, compared to the corresponding period of 2023, Semler Scientific reported:

    • Revenues of $12.4 million, a decrease of $2.7 million, or 18%, compared to $15.1 million.
    • Cost of revenues of $1.1 million, a decrease of $2.3 million, or 67%, compared to $3.4 million. Cost of revenues for the fourth quarter ended December 31, 2023 includes a $2.5 million write-off of prepaid software licenses for Insulin Insights.
    • Total operating expenses, which include cost of revenues, of $8.9 million, a decrease of $3.6 million, or 29%, compared to $12.5 million.
    • Income from operations of $3.5 million, an increase of $1.0 million, or 40%, compared to $2.5 million.
    • Pre-tax income of $32.6 million (which includes an unrealized gain from the change in fair value of Semler Scientific's bitcoin holdings of $28.8 million), an increase of $29.8 million, or 1,058%, compared to $2.8 million.
    • Income tax expense of $3.4 million, or an effective tax rate of 10%, compared to income tax benefit of $1.4 million, or an effective tax benefit of 50%.
    • Net income of $29.2 million or $3.64 per basic share and $3.41 per diluted share, an increase of $25.0 million, or 592%, compared to net income of $4.2 million, or $0.62 per basic share and $0.55 per diluted share.

    Semler Scientific's two largest customers (including their affiliates) comprised 39% and 31% of fourth quarter revenues in 2024, respectively, and its three largest customers comprised 37%, 32% and 11% of fourth quarter 2023 revenues, respectively.

    Notice of Conference Call

    Semler Scientific will host a conference call today at 4:30 p.m. ET. The call will address results of the fourth quarter and year ended December 31, 2024, as well as provide a business update on Semler Scientific's strategies for the near-term future. Questions can be submitted prior to the start of the call to [email protected].

    Participants are encouraged to pre-register for the conference call using the following link: https://dpregister.com/sreg/10196221/fe5ab5166e. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or who are unable to pre-register may dial in by calling:

    Domestic callers: (833) 816–1161

    International callers: (412) 317–0717

    Please specify to the operator that you would like to join the "Semler Scientific Call." The conference call will be archived on Semler Scientific's website at www.semlerscientific.com.

     

    Semler Scientific, Inc.

    Statements of Income

    (In thousands of U.S. Dollars, except share and per share data)































    For the three months ended December 31, 



    For the year ended December 31, 





    2024



    2023



    2024



    2023







    Unaudited





    Unaudited













    Revenues



    $

    12,413



    $

    15,056



    $

    56,294



    $

    68,184

    Operating expenses:

























    Cost of revenues





    1,102





    3,384





    4,759





    6,984

    Engineering and product development





    1,028





    1,207





    4,792





    5,773

    Sales and marketing





    2,971





    4,546





    13,078





    18,147

    General and administrative





    3,770





    3,262





    12,732





    14,290

    Strategic streamlining





    —





    135





    —





    734

    Total operating expenses





    8,871





    12,534





    35,361





    45,928

    Income from operations





    3,542





    2,522





    20,933





    22,256

    Interest and dividend income, net





    179





    699





    1,877





    2,471

    Impairment of investments





    —





    (337)





    —





    (337)

    Change in fair value of notes held for investment





    —





    (90)





    128





    (307)

    Change in fair value of digital assets





    28,850





    —





    24,933





    —

    Other income





    5





    20





    13





    17

    Other income, net





    29,034





    292





    26,951





    1,844

    Pre-tax income





    32,576





    2,814





    47,884





    24,100

    Income tax provision





    3,370





    (1,407)





    6,985





    3,517

    Net income



    $

    29,206



    $

    4,221



    $

    40,899



    $

    20,583

    Net income per share, basic



    $

    3.64



    $

    0.62



    $

    5.66



    $

    3.06

    Weighted average number of shares used in computing basic net income per share





    8,033,757





    6,804,998





    7,228,961





    6,732,806

    Net income per share, diluted



    $

    3.41



    $

    0.55



    $

    5.13



    $

    2.63

    Weighted average number of shares used in computing diluted net income per share





    8,566,619





    7,734,263





    7,980,118





    7,819,159

     

    Semler Scientific, Inc.

    Balance Sheets

    (In thousands of U.S. Dollars, except share and per share data)



















    December 31, 



    December 31, 





    2024



    2023

    Assets













    Current Assets:













    Cash and cash equivalents



    $

    8,819



    $

    57,200

    Restricted cash





    133





    132

    Trade accounts receivable, net of allowance for credit losses of $199 and $287, respectively





    4,378





    6,125

    Short-term notes held for investment





    6,100





    —

    Inventory, net





    358





    445

    Prepaid expenses and other current assets





    2,900





    2,042

    Total current assets





    22,688





    65,944

    Assets for lease, net





    1,423





    2,285

    Property and equipment, net





    487





    720

    Long-term investments





    512





    512

    Notes held for investment





    —





    5,372

    Intangible digital assets





    214,633





    —

    Other non-current assets





    85





    270

    Deferred tax assets





    —





    2,962

    Total assets



    $

    239,828



    $

    78,065















    Liabilities and Stockholders' Equity













     Current liabilities:













    Accounts payable



    $

    140



    $

    402

    Accrued expenses





    5,173





    4,502

    Deferred revenue





    774





    1,120

    Other short-term liabilities





    226





    176

    Total current liabilities





    6,313





    6,200















    Long-term liabilities:













    Deferred tax liability





    2,765





    —

    Other long-term liabilities





    —





    70

    Total long-term liabilities





    2,765





    70

    Commitments and contingencies













    Stockholders' equity:













    Common stock, $0.001 par value; 50,000,000 shares authorized; 9,770,908 and 7,099,441 shares

    issued, and 9,556,486 and 6,885,019 shares outstanding (treasury shares of 214,422 and 214,422),

    respectively





    9





    7

    Additional paid-in capital





    130,039





    11,985

    Retained earnings





    100,702





    59,803

    Total stockholders' equity





    230,750





    71,795















    Total liabilities and stockholders' equity



    $

    239,828



    $

    78,065

     

    Semler Scientific, Inc.

    Statements of Cash Flows

    (In thousands of U.S. Dollars)



















    For the year ended December 31, 





    2024



    2023

    CASH FLOWS FROM OPERATING ACTIVITIES:













    Net income



    $

    40,899



    $

    20,583















    Reconciliation of Net Income to Net Cash Provided by Operating Activities:













     Depreciation





    579





    599

     Deferred tax expense (income)





    5,727





    (664)

     Loss on disposal of assets for lease





    298





    369

     Write off of prepaid software licenses





    —





    2,476

     Gain on short-term investments





    —





    (151)

     Allowance for credit losses





    (88)





    268

     Change in fair value of notes held for investment





    (128)





    307

     Change in fair value of digital assets





    (24,933)





    —

     Stock-based compensation





    862





    944

     Impairment of long-term investments





    —





    337

    Changes in Operating Assets and Liabilities:













     Trade accounts receivable





    1,844





    (2,508)

     Inventory





    88





    24

     Prepaid expenses and other current assets





    (865)





    (603)

     Other non-current assets





    85





    96

     Accounts payable





    (262)





    (433)

     Accrued expenses





    671





    (246)

     Other current and non-current liabilities





    (367)





    (68)

    Net Cash Provided by Operating Activities





    24,410





    21,330















    CASH FLOWS FROM INVESTING ACTIVITIES:













    Additions to property and equipment





    (51)





    (345)

    Purchase of notes held for investment





    (500)





    (1,000)

    Purchase of digital assets





    (189,700)





    —

    Proceeds from maturities of short-term investments





    —





    78,093

    Purchase of short-term investments





    —





    (57,869)

    Proceeds from sale (purchase) of assets for lease





    269





    (483)

    Net Cash (Used in) Provided by Investing Activities





    (189,982)





    18,396















    CASH FLOWS FROM FINANCING ACTIVITIES:













    Proceeds from issuance of common stock





    119,602





    —

    Taxes paid related to net settlement of equity awards





    (874)





    (3,510)

    Common stock warrants acquired





    —





    (1,949)

    Stock issuance expenses





    (3,000)





    —

    Proceeds from exercise of stock options





    1,464





    51

    Net Cash Provided by (Used in) Financing Activities





    117,192





    (5,408)

    NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS





    (48,380)





    34,318

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD





    57,332





    23,014

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD



    $

    8,952



    $

    57,332

    Supplemental Disclosure of Cash Flow Information:













    Cash paid for taxes



    $

    2,260



    $

    4,060

     

    Semler Scientific, Inc.

    Digital Assets- Additional Information

    Rollforward of bitcoin holdings

    (in thousands of us dollars, except bitcoin held and price per bitcoin)



































    Source of   























    Approximate 



    Capital

























    Average



    Used to

























    Purchase



    Purchase



    Digital Assets



    Change in              



    Digital Assets

    Approximate 



    Price Per



    Bitcoin



    at Cost



    Fair Value



    at Fair Value

    Bitcoin Held



    Bitcoin (in $)

    Balance as of December 31, 2023





    $

    —



    $

    —



    $

    —



    —



    $

    —

    Digital assets purchased







    —





    —





    —



    —





    —

    Balance as of March 31, 2024







    —





    —





    —



    —





    —

    Digital assets purchased

    (a)





    60,000





    —





    60,000



    877





    68,436

    Change in fair value of the digital assets







    —





    (5,055)





    (5,055)



    —





    —

    Balance as of June 30, 2024





    $

    60,000



    $

    (5,055)



    $

    54,945



    877



    $

    68,436

    Digital assets purchased

    (b)





    8,400





    —





    8,400



    141





    59,372

    Change in fair value of the digital assets







    —





    1,137





    1,137



    —





    —

    Balance as of September 30, 2024





    $

    68,400



    $

    (3,918)



    $

    64,482



    1,018



    $

    59,372

    Digital assets purchased

    (b)





    121,300





    —





    121,300



    1,280





    94,755

    Change in fair value of the digital assets







    —





    28,851





    28,851



    —





    —

    Balance as of December 31, 2024





    $

    189,700



    $

    24,933



    $

    214,633



    2,298



    $

    82,538





    (a)

    Cash from operations

    (b)

    Cash from operations and proceeds from ATM offering.

    Important Information about BTC Yield Key Performance Indicator (KPI)

    Semler Scientific uses BTC Yield as a KPI to help assess the performance of its strategy of acquiring bitcoin in a manner Semler Scientific believes is accretive to stockholders. Semler Scientific believes this KPI can be used to supplement an investor's understanding of Semler Scientific's decision to fund the purchase of bitcoin by issuing additional shares of its common stock. When Semler Scientific uses this KPI, management also takes into account the various limitations of this metric.

    BTC Yield is a KPI that represents the percentage change period-to-period of the ratio between Semler Scientific's bitcoin holdings and its Assumed Diluted Shares Outstanding. Assumed Diluted Shares Outstanding refers to the aggregate of Semler Scientific's actual shares of common stock outstanding as of the end of each period plus all additional shares that would result from the assumed exercise of all outstanding stock option awards. Assumed Diluted Shares Outstanding is not calculated using the treasury method and does not take into account any vesting conditions or the exercise price of any stock option awards.

    Additionally, this KPI is not, and should not be understood as, an operating performance measure or a financial or liquidity measure. In particular, BTC Yield is not equivalent to a "yield" in the traditional financial context. It is not a measure of the return on investment Semler Scientific's stockholders may have achieved historically or can achieve in the future by purchasing stock of Semler Scientific, or a measure of income generated by Semler Scientific's operations or its bitcoin holdings, return on investment on its bitcoin holdings, or any other similar financial measure of the performance of its business or assets.

    The trading price of Semler Scientific's common stock is informed by numerous factors in addition to the amount of bitcoins Semler Scientific holds and number of actual or potential shares of its stock outstanding. As a result, the market value of Semler Scientific's shares may trade at a discount or a premium relative to the market value of the bitcoin Semler Scientific holds. BTC Yield is not indicative nor predictive of the trading price of Semler Scientific's shares of common stock. As noted above, this KPI is narrow in its purpose and is used by management to assist in assessing whether Semler Scientific is using equity capital in a manner accretive to stockholders solely as it pertains to its bitcoin holdings.

    In calculating this KPI, Semler Scientific does not take into account the source of capital used for the acquisition of its bitcoin. Semler Scientific notes in particular, it has acquired bitcoin using cash flow from operations, as well as proceeds from the sale of shares in the ATM offering and sale of the notes. Accordingly, this metric might overstate or understate the accretive nature of Semler Scientific's use of equity capital to buy bitcoin because not all bitcoin may be acquired using proceeds of equity and debt offerings and not all issuances of equity may involve the acquisition of bitcoin.

    Semler Scientific's ability to achieve positive BTC Yield may depend on a variety of factors, including its ability to generate cash from operations in excess of its fixed charges and other expenses, as well as factors outside of its control, such as the availability of debt and equity financing on favorable terms. Past performance is not indicative of future results.

    Semler Scientific has historically not paid dividends on its shares of common stock, and by presenting this KPI, Semler Scientific makes no suggestion that it intends to do so in the future. Ownership of common stock does not represent an ownership interest in the bitcoin Semler Scientific holds.

    Investors should rely on the financial statements and other disclosures contained in Semler Scientific's SEC filings. This KPI is merely a supplement, not a substitute. It should be used only by sophisticated investors who understand its limited purpose and many limitations.

    About Semler Scientific, Inc.:

    Semler Scientific, Inc. is a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases. Its flagship product, QuantaFlo®, which is patented and cleared by the U.S. Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and Semler Scientific is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). Semler Scientific also invests in bitcoin and has adopted Bitcoin as its primary treasury asset. Additional information about Semler Scientific can be found at www.semlerscientific.com.

    Forward-Looking Statements

    This press release contains "forward-looking" statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "believe," "goal," "may," "will," "intend," "expect," "anticipate," "estimate," "project," "would," "could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include express or implied statements regarding acquiring and holding bitcoin; as well as innovation and growth in its healthcare business; and sales of securities under the Sales Agreement and other financings to support additional bitcoin purchases including the notes and; seeking a new 510(k) clearance for QuantaFlo with expanded indications; among others. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific's actual results to differ materially from those discussed here, such as risks inherent with investing in bitcoin, including bitcoin's volatility; risk of implementing a new bitcoin treasury strategy; risk that insurance plans and other customers will not continue to license its cardiovascular testing products; risk of changes in the reimbursement landscape for its customers including related to the Centers for Medicare and Medicaid Services (CMS) rate announcement; risk of obtaining a new 510(k) clearance for expanded indications; along with those other risk factors detailed in Semler Scientific's filings with the Securities and Exchange Commission. These forward-looking statements involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of this press release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.

    No Offer or Solicitation

    This press release does not and shall not constitute an offer to sell or a solicitation of an offer to buy any securities of Semler Scientific, Inc., nor shall there be any offer, solicitation or sale of such securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    INVESTOR CONTACT:

    Renae Cormier

    Chief Financial Officer

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/semler-scientific-reports-fourth-quarter-and-full-year-2024-financial-results-with-a-btc-yield-of-107-since-july-1--2024-now-holds-3-192-btc-302379320.html

    SOURCE Semler Scientific, Inc.

    Get the next $SMLR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SMLR

    DatePrice TargetRatingAnalyst
    11/2/2022$60.00 → $45.00Buy → Neutral
    B. Riley Securities
    3/7/2022$145.00 → $70.00Buy
    B. Riley Securities
    11/2/2021$175.00 → $145.00Buy
    B. Riley Securities
    10/26/2021$151.00 → $175.00Buy
    B. Riley Securities
    More analyst ratings

    $SMLR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Semler Scientific® Appoints Natalie Brunell to its Board of Directors

      CAMPBELL, Calif., May 19, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, announced the appointment of Natalie Brunell to its board of directors. This strategic addition reflects Semler Scientific's continued commitment to its Bitcoin treasury strategy and further strengthens its leadership within the Bitcoin community. "We are thrilled to welcome Natalie to our board of directors," said Eric Semler, chairman of Semler Sci

      5/19/25 8:00:00 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific® Reports First Quarter 2025 Financial Results, BTC Yield of 22.2% YTD; Now holds 3,808 BTC

      CAMPBELL, Calif., May 13, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its bitcoin holdings and other key performance indicators (KPIs). "We continue to accretively grow our bitcoin arsenal using operating cash flow and proceeds from debt and equity financings," said Eric Semler, chairman of Semler Scientific. "And we a

      5/13/25 4:01:00 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific® Announces Updated BTC & ATM Activity; Purchased Additional 165 BTC; Now Holds 3,467 BTC; YTD BTC Yield of 23.8%; Earnings Release Date and Conference Call for First Quarter 2025 Financial Results

      SANTA CLARA, Calif., April 30, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today announced updates regarding its bitcoin (BTC) activity, holdings and yield, its at-the-market equity offering (ATM) program and first quarter earnings release date and conference call. BTC Update Between April 25, 2025 and April 29, 2025, Semler Scientific acquired 165 bitcoins for $15.7 million with an average purchase price of $94,931 pe

      4/30/25 8:00:00 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SMLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Brunell Natalie

      4 - Semler Scientific, Inc. (0001554859) (Issuer)

      5/22/25 6:19:47 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Brunell Natalie

      3 - Semler Scientific, Inc. (0001554859) (Issuer)

      5/22/25 6:18:05 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Cormier Renae

      4 - Semler Scientific, Inc. (0001554859) (Issuer)

      5/5/25 9:12:05 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SMLR
    Leadership Updates

    Live Leadership Updates

    See more
    • Semler Scientific® Appoints Natalie Brunell to its Board of Directors

      CAMPBELL, Calif., May 19, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, announced the appointment of Natalie Brunell to its board of directors. This strategic addition reflects Semler Scientific's continued commitment to its Bitcoin treasury strategy and further strengthens its leadership within the Bitcoin community. "We are thrilled to welcome Natalie to our board of directors," said Eric Semler, chairman of Semler Sci

      5/19/25 8:00:00 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific Announces Appointment of Chief Financial Officer, Record Quarterly Revenues and Strategic Streamlining

      SANTA CLARA, Calif., July 11, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced the appointment of a chief financial officer (CFO), record quarterly revenues expected for the second quarter of 2023 and a strategic streamlining. "We are pleased to announce Ms. Renae Cormier will lead our accounting, finance, investor relations and business strategy efforts as chief financial officer," said Doug Murphy-Chuto

      7/11/23 8:03:00 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific Announces Appointment of Eric Semler and William Chang as Directors

      Eric Semler Appointed as Chairman SANTA CLARA, Calif., April 19, 2023 /PRNewswire/ -- - Semler Scientific, Inc. (NASDAQ:SMLR) today announced that Eric Semler and William H.C. Chang (together, the "Investors"), who collectively beneficially own more than 20% of Semler Scientific's outstanding shares, will immediately join Semler Scientific's board of directors as new independent directors. Mr. Semler will join the board as a Class II director standing for reelection at the 2023 annual meeting of stockholders and will be appointed as Chairman of the board, and Mr. Chang will join the board as a Class I director standing for reelection at the 2025 annual meeting of stockholders. The board will

      4/19/23 4:01:00 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SMLR
    SEC Filings

    See more
    • Semler Scientific Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Semler Scientific, Inc. (0001554859) (Filer)

      6/4/25 5:00:25 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

      8-K - Semler Scientific, Inc. (0001554859) (Filer)

      6/4/25 8:00:10 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

      8-K - Semler Scientific, Inc. (0001554859) (Filer)

      5/23/25 8:00:12 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SMLR
    Financials

    Live finance-specific insights

    See more
    • Semler Scientific® Reports First Quarter 2025 Financial Results, BTC Yield of 22.2% YTD; Now holds 3,808 BTC

      CAMPBELL, Calif., May 13, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its bitcoin holdings and other key performance indicators (KPIs). "We continue to accretively grow our bitcoin arsenal using operating cash flow and proceeds from debt and equity financings," said Eric Semler, chairman of Semler Scientific. "And we a

      5/13/25 4:01:00 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific® Announces Updated BTC & ATM Activity; Purchased Additional 165 BTC; Now Holds 3,467 BTC; YTD BTC Yield of 23.8%; Earnings Release Date and Conference Call for First Quarter 2025 Financial Results

      SANTA CLARA, Calif., April 30, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today announced updates regarding its bitcoin (BTC) activity, holdings and yield, its at-the-market equity offering (ATM) program and first quarter earnings release date and conference call. BTC Update Between April 25, 2025 and April 29, 2025, Semler Scientific acquired 165 bitcoins for $15.7 million with an average purchase price of $94,931 pe

      4/30/25 8:00:00 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific® Announces Updated BTC & ATM Activity; Purchased Additional 111 BTC; Now Holds 3,303 BTC; YTD BTC Yield of 23.5%

      SANTA CLARA, Calif., April 25, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to assist its customers in evaluating and treating chronic diseases, today announced updates regarding its bitcoin (BTC) activity, holdings and yield, as well as its at-the-market equity offering (ATM) programs. BTC Update Between February 14, 2025 and April 24, 2025, Semler Scientific acquired 111 bitcoins for $10.0 million with an average purchase price of $90,124 per bitcoin, inclusive of fees and expenses, using p

      4/25/25 8:00:00 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SMLR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SMLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SMLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Director Semler Eric was granted 1,318 shares and bought $1,896,500 worth of shares (50,000 units at $37.93), increasing direct ownership by 9% to 621,721 units (SEC Form 4)

      4 - Semler Scientific, Inc. (0001554859) (Issuer)

      11/12/24 6:05:40 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Semler Scientific downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Semler Scientific from Buy to Neutral and set a new price target of $45.00 from $60.00 previously

      11/2/22 6:23:13 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • B. Riley Securities reiterated coverage on Semler Scientific with a new price target

      B. Riley Securities reiterated coverage of Semler Scientific with a rating of Buy and set a new price target of $70.00 from $145.00 previously

      3/7/22 10:22:03 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • B. Riley Securities reiterated coverage on Semler Scientific with a new price target

      B. Riley Securities reiterated coverage of Semler Scientific with a rating of Buy and set a new price target of $145.00 from $175.00 previously

      11/2/21 10:00:22 AM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

      SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

      12/12/24 4:16:00 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Semler Scientific Inc.

      SC 13G - Semler Scientific, Inc. (0001554859) (Subject)

      11/26/24 12:09:40 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

      SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

      11/12/24 4:15:46 PM ET
      $SMLR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care